Funds and ETFs NovoCure Limited
Equities
NVCR
JE00BYSS4X48
Medical Equipment, Supplies & Distribution
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
12.36 USD | +1.31% | +3.19% | -83.23% |
Nov. 28 | Sector Update: Health Care Stocks Ease Tuesday Afternoon | MT |
Nov. 28 | Sector Update: Health Care | MT |
ETFs positioned on NovoCure Limited
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.90% | 69 M€ | -3.54% | ||
0.88% | 277 M€ | -16.61% | - | |
0.81% | 0 M€ | 0.00% | - | |
0.71% | 0 M€ | 0.00% | - | |
0.57% | 45 M€ | -5.52% | ||
0.57% | 36 M€ | -11.69% | - | |
0.48% | 31 M€ | +4.25% | - | |
0.42% | 55 M€ | -12.98% | - | |
0.39% | 69 M€ | -17.93% | ||
0.36% | 3 M€ | -9.68% | ||
0.35% | 909 M€ | -10.51% | - | |
0.23% | 584 M€ | -3.06% | - | |
0.23% | 47 M€ | +1.86% | ||
0.22% | 34 M€ | -9.43% | - | |
0.22% | 329 M€ | -12.76% | ||
0.22% | 3 M€ | -5.16% | - | |
0.22% | 6,059 M€ | -8.83% | ||
0.20% | 15 M€ | -8.97% | ||
0.19% | 26 M€ | +9.30% | - | |
0.19% | 4,371 M€ | -4.89% | ||
0.17% | 31 M€ | -.--% | ||
0.16% | 0 M€ | 0.00% | - | |
0.16% | 0 M€ | -.--% | - | |
0.16% | 566 M€ | +4.54% | ||
0.16% | 131 M€ | -2.56% | ||
0.14% | 18 M€ | -10.38% | - | |
0.11% | 337 M€ | +9.82% | ||
0.10% | 11,759 M€ | +9.15% | ||
0.09% | 0 M€ | -.--% | - | |
0.09% | 1,337 M€ | +6.89% | ||
0.09% | 3 M€ | +7.00% | ||
0.08% | 10 M€ | -0.99% | - | |
0.08% | 486 M€ | +15.36% | ||
0.08% | 20 M€ | +14.82% | - | |
0.08% | 10,995 M€ | +16.14% | ||
0.07% | 8,594 M€ | +5.87% | ||
0.06% | 90 M€ | +7.85% |
NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company's key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
12.20USD
Average target price
26.14USD
Spread / Average Target
+114.29%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-83.23% | 1 304 M $ | |
+1.64% | 8 668 M $ | |
-18.00% | 6 161 M $ | |
+4.44% | 5 864 M $ | |
+30.57% | 5 192 M $ | |
-36.69% | 4 908 M $ | |
+5.96% | 4 708 M $ | |
+18.63% | 3 386 M $ | |
-5.12% | 3 355 M $ | |
-18.70% | 2 407 M $ |
- Stock
- Equities
- Stock NovoCure Limited - Nasdaq
- Funds and ETFs NovoCure Limited